Torrent Pharmaceuticals
Torrent Pharma delivered a strong Q3 FY26 with 18% revenue growth to ₹3,333 crore and 19% EBITDA growth to ₹1,088 crore, driven by double-digit expansion in India (+14%) and Brazil (+27% reported, +10% constant curren...
Torrent Pharmaceuticals vs Eris Lifesciences Q3 FY26
Side-by-side earnings comparison across verified financials, sentiment, risks, and management commentary.
Eris Lifesciences
Eris Lifesciences reported Q1 FY26 consolidated revenue of ₹773 crore (+7.4% YoY) and PAT of ₹125 crore (+41% YoY), driven by strong domestic branded business (DBS) growth of 11% and margin expansion.
Result Snapshot
Revenue₹3,333 Cr₹807 Cr
PAT₹635 Cr₹109 Cr
EBITDA Margin32.9%35%
Sentimentbullishbullish
Key Quotes
Our two largest branded markets, India and Brazil, each continue to deliver healthy double-digit growth. India business grew at 14% and Brazil grew at 27%.
We retain our position that we expect to be among the first launches in India post LOE.